|
1
|
Loughner CL, Bruford EA, McAndrews MS,
Delp EE, Swamynathan S and Swamynathan SK: Organization, evolution
and functions of the human and mouse Ly6/uPAR family genes. Hum
Genomics. 10:102016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Blasi F and Sidenius N: The urokinase
receptor: Focused cell surface proteolysis, cell adhesion and
signaling. FEBS Lett. 584:1923–1930. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Smith HW and Marshall CJ: Regulation of
cell signalling by uPAR. Nat Rev Mol Cell Biol. 11:23–36. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kim SH, Turnbull J and Guimond S:
Extracellular matrix and cell signalling: The dynamic cooperation
of integrin, proteoglycan and growth factor receptor. J Endocrinol.
209:139–151. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Parnaud G, Hammar E, Ribaux P, Donath MY,
Berney T and Halban PA: Signaling pathways implicated in the
stimulation of beta-cell proliferation by extracellular matrix. Mol
Endocrinol. 23:1264–1271. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Blasi F and Carmeliet P: uPAR: A versatile
signalling orchestrator. Nat Rev Mol Cell Biol. 3:932–943. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Huber MC, Mall R, Braselmann H,
Feuchtinger A, Molatore S, Lindner K, Walch A, Gross E, Schmitt M,
Falkenberg N and Aubele M: uPAR enhances malignant potential of
triple-negative breast cancer by directly interacting with uPA and
IGF1R. BMC Cancer. 16:6152016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jacobsen B and Ploug M: The urokinase
receptor and its structural homologue C4.4A in human cancer:
Expression, prognosis and pharmacological inhibition. Curr Med
Chem. 15:2559–2573. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bené MC, Castoldi G, Knapp W, Rigolin GM,
Escribano L, Lemez P, Ludwig WD, Matutes E, Orfao A, Lanza F, et
al: CD87 (urokinase-type plasminogen activator receptor), function
and pathology in hematological disorders: A review. Leukemia.
18:394–400. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
de Nooij-van Dalen AG, van Dongen GA,
Smeets SJ, Nieuwenhuis EJ, Stigter-van Walsum M, Snow GB and
Brakenhoff RH: Characterization of the human Ly-6 antigens, the
newly annotated member Ly-6K included, as molecular markers for
head-and-neck squamous cell carcinoma. Int J Cancer. 103:768–774.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Matsuda R, Enokida H, Chiyomaru T, Kikkawa
N, Sugimoto T, Kawakami K, Tatarano S, Yoshino H, Toki K, Uchida Y,
et al: LY6K is a novel molecular target in bladder cancer on basis
of integrate genome-wide profiling. Br J Cancer. 104:376–386. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang B, Zhang Z, Zhang X, Gao X,
Kernstine KH and Zhong L: Serological antibodies against LY6K as a
diagnostic biomarker in esophageal squamous cell carcinoma.
Biomarkers. 17:372–378. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
AlHossiny M, Luo L, Frazier WR, Steiner N,
Gusev Y, Kallakury B, Glasgow E, Creswell K, Madhavan S, Kumar R
and Upadhyay G: Ly6E/K Signaling to TGFβ promotes breast cancer
progression, immune escape, and drug resistance. Cancer Res.
76:3376–3386. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kong HK, Park SJ, Kim YS, Kim KM, Lee HW,
Kang HG, Woo YM, Park EY, Ko JY, Suzuki H, et al: Epigenetic
activation of LY6K predicts the presence of metastasis and poor
prognosis in breast carcinoma. Oncotarget. 7:55677–55689. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kong HK, Yoon S and Park JH: The
regulatory mechanism of the LY6K gene expression in human breast
cancer cells. J Biol Chem. 287:38889–38900. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Balakrishnan K and Adams LE: The role of
the lymphocyte in an immune response. Immunol Invest. 24:233–244.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Roth PE and DeFranco AL: Lymphocyte
development: Intrinsic checkpoints for lineage progression. Curr
Biol. 5:349–352. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nagasawa T: Microenvironmental niches in
the bone marrow required for B-cell development. Nat Rev Immunol.
6:107–116. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lai AY and Kondo M: T and B lymphocyte
differentiation from hematopoietic stem cell. Semin Immunol.
20:207–212. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zúñiga-Pflücker JC: T-cell development
made simple. Nat Rev Immunol. 4:67–72. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Germain RN: T-cell development and the
CD4-CD8 lineage decision. Nat Rev Immunol. 2:309–322. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Choi SH, Kong HK, Park SY and Park JH:
Metastatic effect of LY-6K gene in breast cancer cells. Int J
Oncol. 35:601–607. 2009.PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lin J, Zhang Q, Zhu LQ, Yu QH and Yang Q:
The copy number and integration site analysis of IGF-1 transgenic
goat. Int J Mol Med. 34:900–910. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Altschul SF, Gish W, Miller W, Myers EW
and Lipman DJ: Basic local alignment search tool. J Mol Biol.
215:403–410. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Batista FD and Harwood NE: The who, how
and where of antigen presentation to B cells. Nat Rev Immunol.
9:15–27. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xu D, Liu H, Komai-Koma M, Campbell C,
McSharry C, Alexander J and Liew FY: CD4+CD25+ regulatory T cells
suppress differentiation and functions of Th1 and Th2 cells,
Leishmania major infection, and colitis in mice. J Immunol.
170:394–399. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Amu S, Gjertsson I, Tarkowski A and
Brisslert M: B-cell CD25 expression in murine primary and secondary
lymphoid tissue. Scand J Immunol. 64:482–492. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hager-Theodorides AL, Rowbotham NJ, Outram
SV, Dessens JT and Crompton T: Beta-selection: Abundance of
TCRbeta-/gammadelta-CD44-CD25-(DN4) cells in the foetal thymus. Eur
J Immunol. 37:487–500. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Luo L, McGarvey P, Madhavan S, Kumar R,
Gusev Y and Upadhyay G: Distinct lymphocyte antigens 6 (Ly6) family
members Ly6D, Ly6E, Ly6K and Ly6H drive tumorigenesis and clinical
outcome. Oncotarget. 7:11165–11193. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kim YS, Park SJ, Lee YS, Kong HK and Park
JH: miRNAs involved in LY6K and estrogen receptor α contribute to
tamoxifen-susceptibility in breast cancer. Oncotarget.
7:42261–42273. 2016.PubMed/NCBI
|
|
32
|
Bryant CD, Zhang NN, Sokoloff G, Fanselow
MS, Ennes HS, Palmer AA and McRoberts JA: Behavioral differences
among C57BL/6 substrains: Implications for transgenic and knockout
studies. J Neurogenet. 22:315–331. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Simon MM, Greenaway S, White JK, Fuchs H,
Gailus-Durner V, Wells S, Sorg T, Wong K, Bedu E, Cartwright EJ, et
al: A comparative phenotypic and genomic analysis of C57BL/6J and
C57BL/6N mouse strains. Genome Biol. 14:R822013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dudley JP, Golovkina TV and Ross SR:
Lessons learned from mouse mammary tumor virus in animal models.
ILAR J. 57:12–23. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ross SR: Mouse mammary tumor virus
molecular biology and oncogenesis. Viruses. 2:2000–2012. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Taneja P, Frazier DP, Kendig RD, Maglic D,
Sugiyama T, Kai F, Taneja NK and Inoue K: MMTV mouse models and the
diagnostic values of MMTV-like sequences in human breast cancer.
Expert Rev Mol Diagn. 9:423–440. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Fantozzi A and Christofori G: Mouse models
of breast cancer metastasis. Breast Cancer Res. 8:2122006.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yang G, Park S, Cao G, Goltsov A, Ren C,
Truong LD, Demayo F and Thompson TC: MMTV promoter-regulated
caveolin-1 overexpression yields defective parenchymal epithelia in
multiple exocrine organs of transgenic mice. Exp Mol Pathol.
89:9–19. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bérard J, Gaboury L, Landers M, De
Repentigny Y, Houle B, Kothary R and Bradley WE: Hyperplasia and
tumours in lung, breast and other tissues in mice carrying a RAR
beta 4-like transgene. EMBO J. 13:5570–5580. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Davies BR, Platt-Higgins AM, Schmidt G and
Rudland PS: Development of hyperplasias, preneoplasias, and mammary
tumors in MMTV-c-erbB-2 and MMTV-TGFα transgenic rats. Am J Pathol.
155:303–314. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Haraguchi S, Good RA, Engelman RW and Day
NK: Human prolactin regulates transfected MMTV LTR-directed gene
expression in a human breast-carcinoma cell line through
synergistic interaction with steroid hormones. Int J Cancer.
52:928–933. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kennedy R and Celis E: Multiple roles for
CD4+ T cells in anti-tumor immune responses. Immunol Rev.
222:129–144. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Pluhar GE, Pennell CA and Olin MR:
CD8+ T Cell-independent immune-mediated mechanisms of
anti-tumor activity. Crit Rev Immunol. 35:153–172. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Huppa JB and Davis MM: T-cell-antigen
recognition and the immunological synapse. Nat Rev Immunol.
3:973–983. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Pardoll DM and Topalian SL: The role of
CD4+ T cell responses in antitumor immunity. Curr
Opinion Immunol. 10:588–594. 1998. View Article : Google Scholar
|
|
46
|
Kast WM, Offringa R, Peters PJ, Arie CV,
Rob HM, Alex JV and Cornelis JMM: Eradication of adenovirus
E1-induced tumors by E1A-specific cytotoxic T lymphocytes. Cell.
59:603–614. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Haabeth OA, Tveita AA, Fauskanger M,
Schjesvold F, Lorvik KB, Hofgaard PO, Omholt H, Munthe LA, Dembic
Z, Corthay A and Bogen B: How Do CD4(+) T cells detect and
eliminate tumor cells that either lack or express MHC Class II
molecules? Front Immunol. 5:1742014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Gao FG, Khammanivong V, Liu WJ, Leggatt
GR, Frazer IH and Fernando GJ: Antigen-specific CD4+ T-cell help is
required to activate a memory CD8+ T cell to a fully functional
tumor killer cell. Cancer Res. 62:6438–6441. 2002.PubMed/NCBI
|
|
49
|
Zanetti M: Tapping CD4 T cells for cancer
immunotherapy: The choice of personalized genomics. J Immunol.
194:2049–2056. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wang RF: The role of MHC class
II-restricted tumor antigens and CD4+ T cells in
antitumor immunity. Trends Immunol. 22:269–276. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Sehgal I, Foster TP and Francis J:
Prostate cancer cells show elevated urokinase receptor in a mouse
model of metastasis. Cancer Cell Int. 6:212006. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Park SB, Kim HH, Shin HJ, Paik MH, Kim DB
and Gong G: Thymic metastasis in breast cancer: A case report.
Korean J Radiol. 8:360–363. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Peters HC, Liu X, Iqbal A, Cunningham LA
and Tan SA: Colorectal cancer metastasis to the thymus gland: Rare
presentation of colorectal cancer as anterior mediastinal mass.
Case Rep Surg. 2017:65819652017.PubMed/NCBI
|
|
54
|
Hayashi S, Hamanaka Y, Sueda T, Yonehara S
and Matsuura Y: Thymic metastasis from prostatic carcinoma: Report
of a case. Surg Today. 23:632–634. 1993. View Article : Google Scholar : PubMed/NCBI
|
